Company news
Vivani Medical, Inc. news in 2025
Vivani Medical, Inc.'s news releases, calls and decks from 2025, newest first.
Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results
November 13, 2025
Vivani Medical to Present at the ThinkEquity Conference on October 30, 2025
October 22, 2025
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
October 3, 2025
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025
September 24, 2025
Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders
September 17, 2025
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
September 4, 2025
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
August 20, 2025
Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results
August 13, 2025
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
August 5, 2025
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
June 11, 2025
Vivani Medical to Present at the 2025 BIO International Convention
June 10, 2025
Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders
May 29, 2025
Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results
May 13, 2025
Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop
May 7, 2025
Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company
April 16, 2025
Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
April 15, 2025
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 31, 2025
Vivani Medical Announces $8.25M Private Placement Equity Financing
March 27, 2025
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
March 26, 2025
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
March 24, 2025
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
March 13, 2025
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
March 12, 2025
Decks in 2025
- Corporate Update (November 2025)
Corporate update · 26 slides · Nov 13, 2025
- Investor Presentation (September 2025)
Investor deck · 26 slides · Sep 9, 2025
- Q2 2025 Earnings Presentation
Earnings · 35 slides · Aug 13, 2025
- Investor Presentation (June 2025)
Investor deck · 39 slides · Jun 17, 2025
- Investor Presentation (March 2025)
Investor deck · 36 slides · Mar 31, 2025